Athira Pharma, Inc.  allegedly omitted crucial truths about its CEO and President in the Registration Statement for its initial public offering (IPO), eventually causing investors to lose significant amounts of money. If you purchased or acquired ATHA common stock pursuant to or traceable to the IPO, please contact Keller Rohrback at [email protected] or (800) 776-6044.